This activity features flashcards covering key topics from Integrating New Treatments for HER2+ Early Breast Cancer: Time for a Risk-Adapted Approach, a satellite symposium held in Madrid.
To access the downloadable slides from this symposium, please click here.
Oct 13, 2017
Oct 13, 2018
This educational activity is specifically designed for oncologists and other healthcare professionals interested in and/or involved in the treatment of breast cancer that wish to understand some of the latest developments in treatments for patients with HER2+ breast cancer.
After successful completion of this educational activity, participants should be able to:
- Evaluate the results of recent clinical trials in HER2+ early breast cancer that explore the evolution of adjuvant treatment strategies
- Select the optimum HER2-targeted strategy and duration of treatment to improve long-term disease endpoints in patients with HER2+ early breast cancer
- Identify supportive care interventions to minimize adverse events with HER2-targeted therapy
- Understand the limitations of health care funding for HER2+ early breast cancer and the need for a risk-adapted strategy
This educational activity is supported by a grant from Puma Biotechnology.
Enduring Materials From a Certified Activity
This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.
This enduring activity is provided by prIME Oncology.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.